

## New Class of Anticancer Chemotherapy Agents

**Track Code:** 2017-GHOS-67971

**Categories:**

- Medical/Health
- Pharmaceuticals

**Keywords:**

- Chemotherapy
- Medical/Health
- Pharmaceuticals

According to the National Cancer Institute, approximately 40 percent of people will be diagnosed with cancer in their lifetime and worldwide number of diagnostics are predicted to increase nearly 50 percent by 2030. Nearly 2 percent of all men and 1.5 percent of all women are killed each year by cancer. Cancer is simply described as continuous and uncontrolled division of cells leading to tumors. With the increase in cancer cases worldwide and the lack of a consistent treatment, new development are still needed in the field.

Researchers at Purdue University have synthesized a number of natural products that inhibit cell splicing. These herboxidiene derivatives inhibit cell division through its interactions with the proteins responsible for pre-mRNA splicing. This technology shows potential for use in a variety of select human cancers with increased functionality and consistent stability and potency.

**Advantages:**

- Stable and potent
- Appropriate drug functionalities for conjugates

**Potential Applications:**

- Pharmaceuticals
- Anticancer, chemotherapy drugs

**People:**

- Ghosh, Arun K (Project leader)
- Jurica, Melissa

**Intellectual Property:**

**Application Date:** January 24, 2020

**Type:** NATL-Patent

**Country of Filing:** United States  
**Patent Number:** (None)  
**Issue Date:** (None)

**Application Date:** July 26, 2018  
**Type:** PCT-Patent  
**Country of Filing:** WO  
**Patent Number:** (None)  
**Issue Date:** (None)

**Application Date:** July 26, 2017  
**Type:** Provisional-Patent  
**Country of Filing:** United States  
**Patent Number:** (None)  
**Issue Date:** (None)

**Contact OTC:**

Purdue Office of Technology Commercialization  
The Convergence Center  
101 Foundry Drive, Suite 2500  
West Lafayette, IN 47906

Phone: (765) 588-3475  
Fax: (765) 463-3486  
Email: [otcip@prf.org](mailto:otcip@prf.org)